Early access
Sign in
Taking people in United StatesPhase 2

LY4005130 compared with placebo in adults with non-segmental vitiligo

Tests LY4005130 against placebo in adults with non-segmental vitiligo.

Key facts

Who runs it
Eli Lilly and Company
Where
Boston, Fremont, Humble, Indianapolis, Miami, Northridge, Oxnard, Phoenix, Portsmouth, Richmond, San Antonio, Sandy Springs, Santa Clarita, South Jordan, Tampa, The Bronx, and Troy, United StatesSee the 18 sitesAlso in 4 other countries, 17 sites
Registry title
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Status
Recruiting
Phase
Phase 2
People taking part
66 people, planned
Started
14 Apr 2026
Expected to end
Sept 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • LY4005130
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with non-segmental vitiligo, a condition where skin loses its color in patches. It compares LY4005130, given into a vein, with placebo.

Age
18 Years to 75 Years
Sex
All sexes can join.
Disease stage
Non-segmental vitiligo diagnosed at least 3 months ago. Patches cover 4% to 60% of the body, not counting palms, soles or tops of the feet. At least 0.5% of the face is affected. F-VASI ≥0.5 and T-VASI ≥3. The disease can be active or stable.
Earlier treatment
People who ever had a JAK inhibitor, as pills or cream (for example ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib), cannot join.

Main reasons for not taking part

  • Other types of vitiligo, or other active skin color disorders
  • Active inflammatory skin disease or skin problems that would affect checking the vitiligo
  • Skin surface infection within 2 weeks before the start; rescreening is possible after it clears
  • Chronic alcohol abuse or drug abuse within 1 year before screening
  • Serious or unstable illness of the heart, lungs, liver, gut, hormones, blood, nerves or mind

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Eligible participants must have the following at both screening and baseline:; A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months; Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet; BSA involvement of ≥0.5% on the face; F-VASI ≥0.5 and T-VASI ≥3, and; Either active or stable disease at both screening and baseline

Who cannot take part

  • Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved
  • Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening
  • Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve
  • Currently have active forms of other disorders of pigmentation
  • Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data
  • Participants who have other types of vitiligo that are not considered active or stable vitiligo

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

Also in 4 other countries, 17 sites

  • Brigham and Women's HospitalBoston, United StatesContact: Arash Mostaghimi (principal investigator)Taking people
  • Center For Dermatology Clinical Research, Inc.Fremont, United StatesContact: Sunil Dhawan (principal investigator)Taking people
  • Accurate Clinical Research, IncHumble, United StatesContact: Chinelo Fangtang (principal investigator)Taking people
  • Dawes Fretzin Clinical Research Group, LLCIndianapolis, United StatesContact: Scott Fretzin (principal investigator)Taking people
  • Health Clinical Research, LLCMiami, United StatesContact: Soroush Aghigh (principal investigator)Taking people
  • Northridge Clinical TrialsNorthridge, United StatesContact: Navid Ezra (principal investigator)Taking people
  • Cura Clinical Research - OxnardOxnard, United StatesContact: Michael Lin (principal investigator)Taking people
  • Medical Dermatology SpecialistsPhoenix, United StatesContact: Lindsay Ackerman (principal investigator)Taking people
  • Saguaro Dermatology - PhoenixPhoenix, United StatesContact: Dathan Hamann (principal investigator)Taking people
  • StracskinPortsmouth, United StatesContact: Abel Jarell (principal investigator)Taking people
  • Clinical Research Partners, LLCRichmond, United StatesTaking people
  • Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels AvenueSan Antonio, United StatesContact: John Browning (principal investigator)Taking people
  • Advanced Medical Research, PC.Sandy Springs, United StatesContact: Jamie Weisman (principal investigator)Taking people
  • Cura Clinical Research - Santa Clarita - Kelly Johnson ParkwaySanta Clarita, United StatesContact: Bernard Raskin (principal investigator)Taking people
  • Jordan Valley Dermatology & Research CenterSouth Jordan, United StatesContact: Douglass Forsha (principal investigator)Taking people
  • K2 Medical Research - TampaTampa, United StatesContact: Kelley Wilson (principal investigator)Taking people
  • Equity MedicalThe Bronx, United StatesContact: Maira Fonseca (principal investigator)Taking people
  • Revival Research Institute, LLCTroy, United StatesContact: Ali Moiin (principal investigator)Taking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).

Read full original descriptionShow less

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

The study will last approximately 48 weeks, including screening.

The 2 groups in the trial

  • LY4005130Treatment being tested

    LY4005130 administered intravenously (IV)

  • PlaceboPlacebo, for comparison

    Placebo administered IV

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Plain-language title
LY4005130 compared with placebo in adults with non-segmental vitiligoGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07533019, who can take part
Record updated
4 November 2026